TP53 and B-cell chronic lymphocytic leukemia: The evaluation of chromosome 17p deletion and/or TP53 mutation, as well as IGHV hyper-mutational status, is currently recommended in each patient before starting a new treatment for CLL due to their significant impact on treatment response [5].